<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F1E10788-8795-456D-A1DF-B484F303C6B6"><gtr:id>F1E10788-8795-456D-A1DF-B484F303C6B6</gtr:id><gtr:name>Research and Development AstraZeneca</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F1E10788-8795-456D-A1DF-B484F303C6B6"><gtr:id>F1E10788-8795-456D-A1DF-B484F303C6B6</gtr:id><gtr:name>Research and Development AstraZeneca</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1D0110B4-1EFE-4F47-8047-172C83984EB8"><gtr:id>1D0110B4-1EFE-4F47-8047-172C83984EB8</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7C4F8F1D-17BD-41AD-B555-088A2D0B59C8"><gtr:id>7C4F8F1D-17BD-41AD-B555-088A2D0B59C8</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D33C797B-712D-4BDA-841C-D0E6AFE36362"><gtr:id>D33C797B-712D-4BDA-841C-D0E6AFE36362</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Scott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901615"><gtr:id>3473E047-495D-49EF-9FD7-3A63E7244707</gtr:id><gtr:title>Molecular and pharmacological validation of Cathepsin S as a novel target in cancer treatment</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901615</gtr:grantReference><gtr:abstractText>Malignant cancer is hallmarked by the ability of the tumour to invade its normal surrounding tissue thus permitting its development and spread, frequently to distal sites/organs. The development of these secondary tumours is normally the cause of mortality in the patient. This proposal aims to evaluate the potential for the therapeutic blocking of a destructive enzyme, cathepsin S, in the development and spread of aggressive tumours. Over-produced by tumour and tumour associated cells, the inhibition of this protease may in the future prove useful in combination with chemotherapeutic agents to not only kill the cancer cells but to prevent the spread and seeding of these secondary metastases.</gtr:abstractText><gtr:technicalSummary>The cysteine protease, cathepsin s, has been implicated in the promotion of the invasive and angiogenic phenotypes of aggressive tumours. Normally found in lysosomes of cells with a restricted tissue expression, cathepsin S has been implicated in the progression of aggressive metastatic tumours. Immunohisto- and biochemical characterization of tumour biopsies has revealed expression and secretion of CatS, where it is thought to mediate remodelling of the extracellular matrix, promoting growth and spread of the tumour and tumour-associated cells. The aim of this work is to validate the targeting of cathepsin S as an anti-tumour therapeutic target; and to evaluate therapeutic inhibition of the enzyme in models of primary tumours and metastases. This investigation will involve the application of in vivo synengenic murine studies to examine both tumour development with stratified cathespin S depletion and the evaluation of a novel experimental therapeutic towards cathepsin S.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-22</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>365747</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research and Development AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Toxicology Sciences</gtr:department><gtr:description>project into pulmonary nanoparticle toxicity</gtr:description><gtr:id>49226C72-E55E-41F5-A1A2-0185F42E14C3</gtr:id><gtr:impact>Invited lecture - Visualisation of nanoparticle induced toxicty using protease signatures - Tiers Winter School on proteolysis in Feb 2013</gtr:impact><gtr:partnerContribution>Have supplied expertise and will provide models to examine the methodologies that we produce in the next couple of years</gtr:partnerContribution><gtr:piContribution>We have used our technology and expertise gained during this research project to develop a new research angle that is important in both understanding nanoparticle deposition and monitoring of adverse effects</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F5977E86-DE78-40F5-85EE-7330551B7844</gtr:id><gtr:impact>30 puils who are interested in undertaking careers with biology background in a career session

invited to take part in session again</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters Northern Ireland Regional finals</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EFD82240-7848-4EE1-AF15-5E908A9A6ED9</gtr:id><gtr:impact>judged panelists in rounds of debating

talked to students afterwards about research and research careers</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters, Northern Ireland</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E79EAA54-FC9E-4E74-B4C0-64CB8D1EA6B5</gtr:id><gtr:impact>Acted as judge for the session of three schhools - approx 20 pupils and teachers

Have been asked to take part in a RCUK-led schools teacher training event</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.debatingmatters.com/events/qr/northern_ireland_south_2013_14/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Slovenia Protease meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F8A31D38-8050-4009-B947-39374EB578BF</gtr:id><gtr:impact>Talk of most recent work on CatS, driven by this orginal funding to international scientific community</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Belfast Philosophical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78770186-7A3E-477A-8E2D-C7E977F6397D</gtr:id><gtr:impact>Talked to general public about our work in pancreatic cancer, leading to new debate and interest in the research at QUB</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brainwaves event with families of cancer patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>73C66063-EFED-4422-848F-31952C7E4F39</gtr:id><gtr:impact>100 patients or family members attended an evening of research to discuss areas pertinent to cancer and I reviewed this MRC work as part of that evening

Patients asked how they could help support our work in the future</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit, Armagh</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6AF6573B-6494-41D9-B2EB-48047B89C77F</gtr:id><gtr:impact>30 pupils (6th formers) attended hte workshop to discuss what ressearch is undertaken in school of pharmacy, QUB and what different career aspirations one can have if they do pharmacy at univeristy beyond practising professionally as clinical or community pharmacists

Larger intake of students from that school for the degree</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>89000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2B1AA57F-8EC5-4D04-9C3D-F4B3A10E6B57</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IPS travel funding</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>International Proteolysis Society (IPS)</gtr:fundingOrg><gtr:id>BD74368D-BDED-495D-A53C-17096765E1D8</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have produced cell lines that are compatible with C57 murine hosts that have had the target enzyme depleted by shRNA. these cell lines have been validated molecularly and phenotypically. This work also involved the analysis of many different shRNA construct sequences, leading to the validation and optimisation of several human ans murine specific constructs that will be of interest to other researchers</gtr:description><gtr:id>3B816B8A-962B-4631-9793-A78499725671</gtr:id><gtr:impact>These cell lines represent the first murine model to accurately reflect the scenario of cathepsin s expression in human colorectal cancers and will now be pursued further in future experiments</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MC38 cathepsin S knockdown cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A521076-0B61-410B-B67D-BEE4DA81FD24"><gtr:id>1A521076-0B61-410B-B67D-BEE4DA81FD24</gtr:id><gtr:title>A bioavailable cathepsin S nitrile inhibitor abrogates tumor development.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86686e059000cd9537454d4aab9a9dcc"><gtr:id>86686e059000cd9537454d4aab9a9dcc</gtr:id><gtr:otherNames>Wilkinson RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24087680-58D9-4634-A739-57ED2F67B708"><gtr:id>24087680-58D9-4634-A739-57ED2F67B708</gtr:id><gtr:title>The Emerging Relevance of the Cysteine Protease Cathepsin S in Disease</gtr:title><gtr:parentPublicationTitle>Clinical Reviews in Bone and Mineral Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d774ebbd6b839c110c9c440ccde90150"><gtr:id>d774ebbd6b839c110c9c440ccde90150</gtr:id><gtr:otherNames>Small D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/84E01936-F2DB-4B9C-86D3-69284D10CDE1"><gtr:id>84E01936-F2DB-4B9C-86D3-69284D10CDE1</gtr:id><gtr:title>Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bfdfabd2b54a8f704077040f13482094"><gtr:id>bfdfabd2b54a8f704077040f13482094</gtr:id><gtr:otherNames>Small DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62B1D360-7BBB-4E06-93FE-DDDF0D6F8EF5"><gtr:id>62B1D360-7BBB-4E06-93FE-DDDF0D6F8EF5</gtr:id><gtr:title>CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86686e059000cd9537454d4aab9a9dcc"><gtr:id>86686e059000cd9537454d4aab9a9dcc</gtr:id><gtr:otherNames>Wilkinson RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901615</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>